Literature DB >> 14726813

Technical standards and guidelines for Huntington disease testing.

Nicholas T Potter1, Elaine B Spector, Thomas W Prior.   

Abstract

One mission of the ACMG Laboratory Quality Assurance (QA) Committee is to develop standards and guidelines for clinical genetics laboratories, including cytogenetics, biochemical, and molecular genetics specialties. This document was developed under the auspices of the Molecular Subcommittee of the Laboratory QA Committee by the Huntington Disease (HD) Working Group. These guidelines are not to be interpreted as restrictive or the only approach but to provide a helpful guide. Certainly, appropriately trained and credentialed laboratory directors have flexibility to utilize various testing platforms and design testing strategies with considerable latitude. We felt that it was essential to include technique-specific guidelines of several current technologies commonly used in laboratories providing HD testing, because the technologies discussed are available commercially and are widely utilized. We take the view that these technologies may change, and thus this document may change with future review.

Entities:  

Mesh:

Year:  2004        PMID: 14726813     DOI: 10.1097/01.gim.0000106165.74751.15

Source DB:  PubMed          Journal:  Genet Med        ISSN: 1098-3600            Impact factor:   8.822


  26 in total

1.  Development of genomic reference materials for cystic fibrosis genetic testing.

Authors:  Victoria M Pratt; Michele Caggana; Christina Bridges; Arlene M Buller; Lisa DiAntonio; W Edward Highsmith; Leonard M Holtegaard; Kasinathan Muralidharan; Elizabeth M Rohlfs; Jack Tarleton; Lorraine Toji; Shannon D Barker; Lisa V Kalman
Journal:  J Mol Diagn       Date:  2009-04-09       Impact factor: 5.568

2.  Characterization of the Huntington intermediate CAG repeat expansion phenotype in PHAROS.

Authors:  Annie Killoran; Kevin M Biglan; Joseph Jankovic; Shirley Eberly; Elise Kayson; David Oakes; Anne B Young; Ira Shoulson
Journal:  Neurology       Date:  2013-04-26       Impact factor: 9.910

Review 3.  Genetic diagnosis and testing in clinical practice.

Authors:  Elizabeth McPherson
Journal:  Clin Med Res       Date:  2006-06

Review 4.  Genetic susceptibility testing for neurodegenerative diseases: ethical and practice issues.

Authors:  J Scott Roberts; Wendy R Uhlmann
Journal:  Prog Neurobiol       Date:  2013-04-09       Impact factor: 11.685

5.  Clinical and genetic data of Huntington disease in Moroccan patients.

Authors:  Ahmed Bouhouche; Wafaa Regragui; Hind Lamghari; Khadija Khaldi; Nazha Birouk; Safaa Lytim; Soufiane Bellamine; Yamna Kriouile; Naima Bouslam; El Hachmia Ait Ben Haddou; Mustapha Alaoui Faris; Ali Benomar; Mohamed Yahyaoui
Journal:  Afr Health Sci       Date:  2015-12       Impact factor: 0.927

6.  "Grasping the grey": patient understanding and interpretation of an intermediate allele predictive test result for Huntington disease.

Authors:  A Semaka; L G Balneaves; M R Hayden
Journal:  J Genet Couns       Date:  2012-08-18       Impact factor: 2.537

Review 7.  Prospects for neuroprotective therapies in prodromal Huntington's disease.

Authors:  Abhishek Chandra; Ashu Johri; M Flint Beal
Journal:  Mov Disord       Date:  2014-02-26       Impact factor: 10.338

Review 8.  Next-generation sequencing in the clinic: are we ready?

Authors:  Leslie G Biesecker; Wylie Burke; Isaac Kohane; Sharon E Plon; Ron Zimmern
Journal:  Nat Rev Genet       Date:  2012-11       Impact factor: 53.242

9.  Discovering the family history of Huntington disease (HD).

Authors:  Holly Etchegary
Journal:  J Genet Couns       Date:  2006-04       Impact factor: 2.537

10.  Huntington disease reduced penetrance alleles occur at high frequency in the general population.

Authors:  Chris Kay; Jennifer A Collins; Zosia Miedzybrodzka; Steven J Madore; Erynn S Gordon; Norman Gerry; Mark Davidson; Ramy A Slama; Michael R Hayden
Journal:  Neurology       Date:  2016-06-22       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.